We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
Read MoreHide Full Article
Catalent’s shares rose 7.2% so far this week. The company’s share price surged following the announcement of its acquisition by Novo Holdings, the parent company of Novo Nordisk (NVO - Free Report) .
Catalent entered into a merger agreement with Novo Nordisk’s parent company on Feb 5. Per the agreement, NVO’s parent company will acquire all outstanding shares of Catalent for $63.50 per share in cash. The deal values Catalent at $16.5 billion on an enterprise value basis.
The offered price for each share of CTLT represents a premium of 16.5% to the closing price of its common stock as of Feb 2. The merger is expected to close toward the end of 2024, following shareholders’ and regulatory approvals.
Over the past year, this currently Zacks Rank #3 (Hold) stock fell 18% compared with the industry’s 5.9% decline and the S&P 500’s 208% growth.
Image Source: Zacks Investment Research
More on the News
Over the past several years, Catalent has built a comprehensive end-to-end offering of services and capabilities to drive innovation in the healthcare system and improve patient outcomes. These services and capabilities are likely to offer premium development and manufacturing solutions for pharma and biotech customers with a potential accelerated investment by Novo Holdings.
As a part of the deal, Novo Nordisk will acquire three of Catalent’s fill-finish sites from Novo Holdings for $11 billion, which will support the manufacturing capacity at scale and speed for Novo Nordisk’s diabetes and obesity treatments. The acquisition is expected to gradually increase NVO's filling capacity starting 2026.
Novo Nordisk already has a collaboration agreement with Catalent, under which it uses these three sites to support the manufacturing of its treatments. The acquisition of these facilities will complement the ongoing significant investments by Novo Nordisk in active pharmaceutical ingredients facilities, and the sites will provide strategic flexibility to the existing supply network.
What’s Next?
Catalent’s shares are currently trading close to the acquisition price, so its investors may sell them now and invest in other good stocks. The only exception is that they can pay less tax on their capital gains by selling later.
Cardinal Health carries a Zacks Rank #3 (Hold) at present.
A couple of better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Universal Health Services, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 4.4% for 2024. UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 5.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UHS’ shares have risen 11.7% over the past year compared with the industry’s 18.55% decline.
Integer Holdings, presently carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 45% in the past year compared with the industry’s 2% increase.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
Catalent’s shares rose 7.2% so far this week. The company’s share price surged following the announcement of its acquisition by Novo Holdings, the parent company of Novo Nordisk (NVO - Free Report) .
Catalent entered into a merger agreement with Novo Nordisk’s parent company on Feb 5. Per the agreement, NVO’s parent company will acquire all outstanding shares of Catalent for $63.50 per share in cash. The deal values Catalent at $16.5 billion on an enterprise value basis.
The offered price for each share of CTLT represents a premium of 16.5% to the closing price of its common stock as of Feb 2. The merger is expected to close toward the end of 2024, following shareholders’ and regulatory approvals.
Over the past year, this currently Zacks Rank #3 (Hold) stock fell 18% compared with the industry’s 5.9% decline and the S&P 500’s 208% growth.
Image Source: Zacks Investment Research
More on the News
Over the past several years, Catalent has built a comprehensive end-to-end offering of services and capabilities to drive innovation in the healthcare system and improve patient outcomes. These services and capabilities are likely to offer premium development and manufacturing solutions for pharma and biotech customers with a potential accelerated investment by Novo Holdings.
As a part of the deal, Novo Nordisk will acquire three of Catalent’s fill-finish sites from Novo Holdings for $11 billion, which will support the manufacturing capacity at scale and speed for Novo Nordisk’s diabetes and obesity treatments. The acquisition is expected to gradually increase NVO's filling capacity starting 2026.
Novo Nordisk already has a collaboration agreement with Catalent, under which it uses these three sites to support the manufacturing of its treatments. The acquisition of these facilities will complement the ongoing significant investments by Novo Nordisk in active pharmaceutical ingredients facilities, and the sites will provide strategic flexibility to the existing supply network.
What’s Next?
Catalent’s shares are currently trading close to the acquisition price, so its investors may sell them now and invest in other good stocks. The only exception is that they can pay less tax on their capital gains by selling later.
Catalent, Inc. Price
Catalent, Inc. price | Catalent, Inc. Quote
Zacks Rank and Stocks to Consider
Cardinal Health carries a Zacks Rank #3 (Hold) at present.
A couple of better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Universal Health Services, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 4.4% for 2024. UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 5.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UHS’ shares have risen 11.7% over the past year compared with the industry’s 18.55% decline.
Integer Holdings, presently carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 45% in the past year compared with the industry’s 2% increase.